A Phase II, Open-label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti−PD-L1 Antibody) Compared With Docetaxel in Patients With Non−Small Cell Lung Cancer After Platinum Failure

Trial Profile

A Phase II, Open-label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti−PD-L1 Antibody) Compared With Docetaxel in Patients With Non−Small Cell Lung Cancer After Platinum Failure

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms POPLAR
  • Sponsors Roche
  • Most Recent Events

    • 18 Apr 2018 Results evaluating C-reactive protein (CRP) in clinical trials with atezolizumab (POPLAR and OAK trial) presented at the 109th Annual Meeting of the American Association for Cancer Research
    • 09 Apr 2018 According to Roche Canada media release,Health Canada approves TECENTRIQ (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer.The approval is based on OAK & POPLAR studies.
    • 07 Apr 2018 This trial has been completed in Germany (end date: 2017-12-05)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top